ArticleResearch square2026

Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.

Eziafa Oduah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.